We're #hiring a new Sr. Manager, Drug Product in San Diego, California. Apply today or share this post with your network.
About us
Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
- Website
-
http://www.xencor.com
External link for Xencor
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- Pasadena, California
- Type
- Public Company
- Founded
- 1997
- Specialties
- Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines
Locations
-
Primary
465 N Halstead St
Suite 200
Pasadena, California 91107, US
-
12770 High Bluff Drive Unit 260
San Diego, CA 92130-2077, US
Employees at Xencor
Updates
-
Preclinical data on Xencor's investigational anti #TL1A antibody, XmAb942, were presented at #UEGW2024 by our Vice President of Development Sciences, James Ernst. Dr. Ernst fielded important audience questions about our potential best-in-class molecule, our clinically validated Xtend™ half-life improvement, the translation of #pharmacokinetics for half-life extended molecules from preclinical models to humans, and the importance of thermostability in manufacturing. XmAb942 is in development for patients with inflammatory bowel disease #IBD. We have guided to the first subject entering a Phase 1 clinical study in the fourth quarter of 2024. Our press release and important disclosures on forward-looking statements are available here: https://lnkd.in/gWZ85u9s And our poster is available here: https://xn.cr/?c=2410a
-
We're #hiring a new Director, Clinical Trial Management in San Diego, California. Apply today or share this post with your network.
-
We're #hiring a new Associate Director, TMF Operations in San Diego, California. Apply today or share this post with your network.
-
We're #hiring a new Associate Director, Clinical Pharmacology & Pharmacometrics in Pasadena, California. Apply today or share this post with your network.
-
We're #hiring a new Director, Clinical Science in San Diego, California. Apply today or share this post with your network.
-
Xencor recently announced four new XmAb® programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors. Read more about the updates in our recent press release: https://lnkd.in/e-f5XPff #biotechnology #bispecificantibodies #oncology #autoimmunedisease
-
We're #hiring a new Director, Analytical Sciences in Pasadena, California. Apply today or share this post with your network.
-
We're #hiring a new Sr. Manager, Corporate Communications in Pasadena, California. Apply today or share this post with your network.
-
We're #hiring a new Sr. Manager, Supply Chain in San Diego, California. Apply today or share this post with your network.